search
Back to results

Effect of HIV Protease Inhibitor Drugs on Glucose and Insulin Metabolism

Primary Purpose

HIV Infections

Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Atazanavir/Ritonavir/Lopinavir/ritonavir
Sponsored by
Bristol-Myers Squibb
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for HIV Infections

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: Healthy volunteers

Sites / Locations

  • Clinical Pharmacology Unit, Bristol-Myers Squibb Company

Outcomes

Primary Outcome Measures

Insulin sensitivity by euglycemic hyperinsulinemic clamp method

Secondary Outcome Measures

Insulin sensitivity by oral glucose tolerance
Lipids and lipoproteins

Full Information

First Posted
August 25, 2005
Last Updated
April 7, 2011
Sponsor
Bristol-Myers Squibb
search

1. Study Identification

Unique Protocol Identification Number
NCT00135434
Brief Title
Effect of HIV Protease Inhibitor Drugs on Glucose and Insulin Metabolism
Official Title
Effect of HIV Protease Inhibitor Drugs on Glucose and Insulin Metabolism
Study Type
Interventional

2. Study Status

Record Verification Date
November 2009
Overall Recruitment Status
Completed
Study Start Date
September 2004 (undefined)
Primary Completion Date
June 2005 (Actual)
Study Completion Date
June 2005 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Bristol-Myers Squibb

4. Oversight

5. Study Description

Brief Summary
This study examined the effects of two commonly prescribed HIV drugs on the way the body metabolizes glucose, insulin and fat.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
HIV Infections

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
25 (false)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Atazanavir/Ritonavir/Lopinavir/ritonavir
Primary Outcome Measure Information:
Title
Insulin sensitivity by euglycemic hyperinsulinemic clamp method
Secondary Outcome Measure Information:
Title
Insulin sensitivity by oral glucose tolerance
Title
Lipids and lipoproteins

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy volunteers
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bristol-Myers Squibb
Organizational Affiliation
Bristol-Myers Squibb
Official's Role
Study Director
Facility Information:
Facility Name
Clinical Pharmacology Unit, Bristol-Myers Squibb Company
City
Hamilton
State/Province
New Jersey
ZIP/Postal Code
08690
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Effect of HIV Protease Inhibitor Drugs on Glucose and Insulin Metabolism

We'll reach out to this number within 24 hrs